Publication:
FDG-PET scan in colorectal cancer

dc.contributor.authorsDane, Faysal; Dede, Fuat; Atasoy, Beste M.
dc.date.accessioned2022-03-10T15:25:02Z
dc.date.accessioned2026-01-11T17:39:59Z
dc.date.available2022-03-10T15:25:02Z
dc.date.issued2008
dc.description.abstract[18F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the management of patients with colorectal carcinoma. This technique has an essential role in the staging of patients prior to surgical resection of recurrence and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen, in the assessment of residual masses after treatment, in determining tumor response to therapy in neo-adjuvant settings, and in evaluating colorectal cancer prognosis. It is possible to measure and visualize metabolic changes in cancer cells via FDG-PET. Combined PET/CT scans permit exact localization with anatomical criteria of the hypermetabolic FDG avid malignant lesions. This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.
dc.identifier.doidoiWOS:000258507500010
dc.identifier.issn1306-133X
dc.identifier.urihttps://hdl.handle.net/11424/220073
dc.identifier.wosWOS:000258507500010
dc.language.isotur
dc.publisherAKAD DOKTORLAR YAYINEVI
dc.relation.ispartofUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFDG
dc.subjectPET/CT
dc.subjectcolorectal cancer
dc.subjectPOSITRON-EMISSION-TOMOGRAPHY
dc.subjectCARCINOEMBRYONIC ANTIGEN
dc.subjectLIVER METASTASES
dc.subjectRADIOFREQUENCY ABLATION
dc.subjectF-18-FDG PET
dc.subjectCOLON
dc.subjectRECURRENCE
dc.subjectIMPACT
dc.subjectRESECTION
dc.subjectTHERAPY
dc.titleFDG-PET scan in colorectal cancer
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage128
oaire.citation.issue2
oaire.citation.startPage121
oaire.citation.titleUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
oaire.citation.volume18

Files